# Isomorphic Labs reportedly in talks to raise about $5B at a $50B valuation

> Original title: Bloomberg: Isomorphic Labs, The Alphabet company spun out of Google DeepMind is negotiating a roughly $5B raise at about $50B, with no dr...

- Source: Rohan Paul
- Published: 2026-11-05T01:16:45.000Z
- Bad Influence: https://badinfluence.news/items/ehwdrmnqpgxx6ajyayhbxnstd
- Original: https://x.com/rohanpaul_ai/status/2118150492958437755

## Summary

Isomorphic Labs, the Alphabet company spun out of Google DeepMind, is negotiating a roughly $5B raise at about $50B, according to Bloomberg, with no drug yet tested in people. The company sells a drug-design engine built on AlphaFold 3 that predicts how proteins fold and how candidate molecules bind them, so chemists can rank designs on a computer before synthesis and animal studies.

## Post

Bloomberg: Isomorphic Labs, The Alphabet company spun out of Google DeepMind is negotiating a roughly $5B raise at about $50B, with no drug yet tested in people.

Their product is a drug-design engine built on AlphaFold 3. It predicts how proteins in the body fold and how a candidate drug molecule will latch onto them. 
Chemists normally find this out through slow, expensive lab trial and error, so the engine lets them design and rank molecules on a computer first and only make the promising ones.

If software predicts how a candidate molecule binds its protein target, chemists can drop weak designs before paying for synthesis and animal studies.

Without human data, a $50B price rests on prediction accuracy and pharma partnerships, not evidence that its molecules work in patients.

![](https://badinfluence.news/api/img-proxy?u=https%3A%2F%2Fpbs.twimg.com%2Fmedia%2FHWUtsMpagAARpK3.png&mode=thumb&exp=1794096000&sig=3a3ac8ab6b25a289)